Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study
Open Access
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 131 (1-2) , 219-228
Abstract
No abstract availableKeywords
Funding Information
- Amicus Therapeutics
This publication has 40 references indexed in Scilit:
- Long‐term outcome of enzyme‐replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complicationsJournal of Internal Medicine, 2013
- Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysisGenetics and Molecular Biology, 2012
- Cardiovascular Events in Patients With Fabry DiseaseJACC, 2011
- Left Ventricular Hypertrophy: Major Risk Factor in Patients with Hypertension: Update and Practical Clinical ApplicationsInternational Journal of Hypertension, 2011
- Prognostic Indicators of Renal Disease Progression in Adults with Fabry DiseaseClinical Journal of the American Society of Nephrology, 2010
- Fabry diseaseOrphanet Journal of Rare Diseases, 2010
- Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome SurveyJournal of Medical Genetics, 2009
- Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyNephrology Dialysis Transplantation, 2009
- Mutant α-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycinBiochemical Journal, 2007
- Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry RegistryJournal of Inherited Metabolic Disease, 2007